April 5, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: | NovaBay Pharmaceuticals, Inc. (the “Company”) Form S-3, File No. 333-254744 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3, as amended by Amendment No. 1 to the Form S-3, to become effective as of 5:00 p.m. (Eastern time) on Wednesday, April 7, 2021, or as soon as practicable thereafter.
Very truly yours, | |||
NovaBay Pharmaceuticals, Inc. | |||
By: | /s/ Justin Hall | ||
Justin Hall | |||
Chief Executive Officer and General Counsel | |||
cc: | Abby E. Brown, Squire Patton Boggs (US) LLP | ||
